As the November 2026 midterm elections approach, cannabis reform has unexpectedly surfaced as a prominent political battleground. Federal rescheduling efforts, state-level ballot initiatives, and high-stakes campaign financing are drawing renewed attention from voters and industry operators navigating a complex $30-billion legal cannabis market.
Here is the math. While majorities of U.S. adults consistently support legalization, shifting partisan dynamics have turned the issue into a calculated political lever rather than a straightforward policy debate.
The Bottom Line
- Federal Status: The ongoing review to move cannabis from Schedule I to Schedule III remains under final review as of August 15, 2026, though no formal effective date has been published.
- Tax Impact: Reclassification would eliminate the application of Internal Revenue Code (IRC) §280E, lifting a massive structural tax burden that currently prevents state-licensed operators from deducting standard business expenses. Industry financial models estimate an annual cash flow impact of $5 billion.
Federal Rescheduling Pushes Against Congressional Stalls
The political momentum surrounding cannabis shifted significantly when the president urged the Justice Department to expedite the reclassification of marijuana from a Schedule I drug—alongside heroin and LSD—to Schedule III, a category that includes Tylenol with codeine, ketamine and testosterone. Acting Attorney General Todd Blanche signed an order to reschedule state-licensed medical marijuana, creating immediate friction on Capitol Hill.
According to Federal Election Commission filings, cannabis industry executives and political action committees have contributed roughly $11.5 million to the Trump-aligned super PAC America First Agriculture Action Inc. Prominent operators, including Kim Rivers, CEO of Trulieve, have lobbied the administration directly for relief from onerous federal regulations. Yet the legislative branch remains severely fractured.
More than 20 Republican lawmakers have actively pushed back against the administration’s trajectory. In August 2025, Rep. Paul Gosar (R-AZ) wrote that reclassifying marijuana would be a political miscalculation for the party. Across the aisle, Senate Democrats led by Cory Booker (NJ), Chuck Schumer (NY), and Ron Wyden (OR) reintroduced the Cannabis Administration and Opportunity Act, pressing for complete federal descheduling rather than what they term half measures.
Meanwhile, the bipartisan SAFER Banking Act—which passed the Senate 58-42 in September 2025 to provide safe harbor for depository institutions serving state-licensed cannabis businesses—remains stalled in the House without a scheduled floor vote.
State Ballot Initiatives and Gubernatorial Flashpoints
Voters across six states will directly shape commercial cannabis policy via the ballot box in November 2026, creating localized pressure points for candidates.
Elsewhere, battles are playing out through gubernatorial races and peculiar counter-initiatives. In Massachusetts, voters face “An Act to Restore a Sensible Marijuana Policy,” an initiative funded by Smart Approaches to Marijuana (SAM) that seeks to repeal the state’s 2016 adult-use legalization vote. Polling from the University of New Hampshire indicates that 63% of Massachusetts voters oppose the repeal measure.
| State / Measure | Policy Focus | Proposed Tax / Structure | Political Context |
|---|---|---|---|
| Florida (Amendment 3) | Adult-use sales authorization | 10% state excise tax | Polling shows majority support above 55% among likely voters. |
| Ohio (Issue 2) | Adult-use commercial licensing | 15% combined state and local tax | Expands current medical framework into broader retail market. |
| North Dakota (Measure 5) | Possession and home cultivation | No commercial market established | Narrower voter margins compared to commercial adult-use states. |
| Massachusetts (Repeal Initiative) | Repeal of 2016 recreational vote | Retains medical program only | Funded by SAM; opposed by 63% of surveyed state voters. |
Shifting Public Sentiment and Market Realities
Public backing for cannabis reform exhibits a complex downward trend in national polling data. A Gallup poll shows that 64% of U.S. adults favor legalizing marijuana use, down from 70% in 2023. This contraction is driven primarily by a decline among self-identified Republicans, whose support dropped 13 percentage points over a single year to 40%, while Democratic and independent support remained stable at 85% and 66%, respectively.
Kevin Sabet, CEO of Smart Approaches to Marijuana, argues that the issue may ultimately underperform expectations at the ballot box. Conversely, advocates maintain that grassroots mobilization remains robust in competitive districts where economic arguments regarding tax revenue and operational efficiency hold sway.
If the DEA finalizes its rescheduling rule, the elimination of IRC §280E will alter corporate balance sheets across major operators like Curaleaf, Green Thumb Industries, and Verano Holdings. By unlocking standard operational deductions, the regulatory shift would redirect billions in capital toward expansion and debt servicing, fundamentally altering the financial architecture of the American cannabis sector regardless of midterm election outcomes.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
